NCT03206060View on ClinicalTrials.gov

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
PheochromocytomaParagangliomaNeuroendocrine TumorsNeuroendocrine Neoplasms
Interventions
DRUG

Lu-177-DOTATATE

Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.

DRUG

Ga-68-DOTATATE

Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.

DRUG

F-18-FDG

F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.

DRUG

Amino Acid solution

AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH